Literature Highlights
Each week, we provide COVID-19 research article summaries and the main highlights in an infographic. Please come back weekly for more updated pandemic infographic highlights covering diagnosis, risk factors, treatment, and more.
Neutralizing capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platfom trial
Tackling COVID-19 with neutralizing monoclonal antibodies
Myocarditis following COVID-19 mRNA vaccination
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicenter, randomized, controlled trial
6-month consequences of COVID-19 in patients discharged from hospital: A cohort study
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S COVID-19 Vaccine
‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19
Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons
Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia
Interleukin-6 Receptor Antagonists in Critically III Patients with COVID-19
Prospective Mapping of Viral Mutations That Escape Antibodies Used to Treat COVID-19
Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S COVID-19 Vaccine
Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19
Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Trial
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19
Pre-pandemic Psychiatric Disorders and Risk of COVID-19: A UK Biobank Cohort Analysis
Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19
Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial
Therapeutic Versus Prophylactic Anticoagulation for Severe COVID-19: A Randomized Phase II Clinical Trial (HESACOVID)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Effects of COVID-19 on the Nervous System
COVID-19 Vaccine: A Comprehensive Status Report
Extrapulmonary Manifestations of COVID-19
Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis
Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report
Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-19: A Preliminary Report of a Phase 1/2, Single-Blind, Randomized Controlled Trial
An mRNA vaccine Aganist SARS-CoV-2 – Preliminary Report
Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial
Pilot Prospective Open, Single-arm Multicentre Study on Off-label Use of Tocilizumab in Patients With Severe COVID-19
Observational Study of Hydroxychlaraquine in Hospitalized Patients with COVID-19
Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections
Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital
Biomarkers Associated with COVID-19 Disease Progression
Remdesivir for the Treatment of COVID-19 – Preliminary Report
A Comparative Study on the Clinical Features of COVID-19 Pneumonia to Other Pneumonias
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
Candidate drugs against SARS-CoV-2 and COVID-19
This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc.
Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.Updates in the Treatment and Prevention of COVID-19
Casirivimab and Imdevimab Approved in Japan for the Treatment of Mild-to-Moderate COVID-19
Japan’s Ministry of Health, Labour and Welfare (MHLW) has fully approved the combination of casirivimab and imdevimab to treat patients with mild-to-moderate COVID-19. This marks the first time a monoclonal-antibody cocktail has received full approval to treat COVID-19. This combination therapy is currently authorized for emergency use in more than 20 countries, including the United States, European Union, India, Switzerland, and Canada. The monoclonal antibody cocktail was approved in Japan after results from a phase 3 trial showed a 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients who received casirivimab and imdevimab. The MHLW also reviewed results from a phase 1 trial that analyzed the safety, tolerability, and pharmacokinetics of the combination therapy in Japanese subjects. Multiple analyses have shown that casirivimab and imdevimab retain potency against circulating variants of concern, including Delta (B.1.162.2, first seen in India), Gamma (P.1, first seen in Brazil), and Beta (B.1.351, first seen in South Africa).
Reference
